NEOADJUVANT IMMUNOTHERAPY
Clinical trials for NEOADJUVANT IMMUNOTHERAPY explained in plain language.
Never miss a new study
Get alerted when new NEOADJUVANT IMMUNOTHERAPY trials appear
Sign up with your email to follow new studies for NEOADJUVANT IMMUNOTHERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to shrink rectal tumors and save organs
Disease control Not yet recruitingThis study tests whether adding two immunotherapy drugs to radiation therapy can better shrink advanced rectal cancer than standard chemoradiation. About 342 adults with a specific type of rectal cancer will be randomly assigned to one of three treatment groups. The goal is to se…
Matched conditions: NEOADJUVANT IMMUNOTHERAPY
Phase: PHASE2, PHASE3 • Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to stop liver cancer recurrence before surgery
Disease control Not yet recruitingThis study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 30 adults with early-stage liver cancer (stage IB or IIA) will receive…
Matched conditions: NEOADJUVANT IMMUNOTHERAPY
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can less be more? new study tests smaller lung surgery after immunotherapy
Disease control Not yet recruitingThis study looks at whether a smaller lung surgery after immunotherapy works as well as the standard larger surgery for people with stage II-IIIB non-small cell lung cancer. About 354 patients whose tumors shrank with immunotherapy will choose either a limited or conventional sur…
Matched conditions: NEOADJUVANT IMMUNOTHERAPY
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Chemo-Free hope: new combo before lung surgery shows promise
Disease control Not yet recruitingThis study tests a new approach for people with early-stage lung cancer who cannot or will not take chemotherapy. Before surgery, patients receive a short course of focused radiation (SBRT) combined with immunotherapy (tislelizumab) and an antiangiogenic drug (anlotinib). The goa…
Matched conditions: NEOADJUVANT IMMUNOTHERAPY
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC